Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7.
暂无分享,去创建一个
David A. Orlando | J. Hodgson | J. Carulli | J. Marineau | N. Rajagopal | Darby R Schmidt | E. Olson | C. Fritz | A. Kabro | E. di Tomaso | M. Bradley | Stephane Ciblat | Liv Johannessen | Shanhu Hu | Yixuan Ren | Dana K. Winter | Kristin B Hamman | N. Ke | K. Sprott | Y. Choi | S. Alnemy | Dana K Winter | Darby Schmidt | Michael Bradley | Kristin B. Hamman | Christian C. Fritz | Yoon Jong Choi | J. Graeme Hodgson | Eric R. Olson
[1] M. McKeown,et al. Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia , 2018, Haematologica.
[2] K. Lei,et al. Inhibition of cyclin‐dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis , 2018, Journal of cellular biochemistry.
[3] T. Giordano,et al. Transcriptional targeting of oncogene addiction in medullary thyroid cancer. , 2018, JCI insight.
[4] D. Taatjes,et al. The essential and multifunctional TFIIH complex , 2018, Protein science : a publication of the Protein Society.
[5] R. Bernards,et al. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma , 2018, Cell Research.
[6] R. Young,et al. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. , 2018, The Journal of investigative dermatology.
[7] J. Tyner,et al. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma. , 2017, Cancer research.
[8] Astrid Gall,et al. Ensembl 2018 , 2017, Nucleic Acids Res..
[9] R. Young,et al. Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. , 2017, Cancer discovery.
[10] Darren L. Smith,et al. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.
[11] Jeremy R. Jacobsen,et al. Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications. , 2017, Cell reports.
[12] Ann E. Sizemore,et al. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.
[13] Zhenfeng Zhang,et al. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer , 2017, Molecular Cancer Therapeutics.
[14] G. O'Neill,et al. Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma , 2017, Oncogenesis.
[15] R. Young,et al. Transcriptional Addiction in Cancer , 2017, Cell.
[16] F. Robert,et al. The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. , 2016, Journal of molecular biology.
[17] Ming-Rong Wang,et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma , 2016, Gut.
[18] P. Sorger,et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.
[19] R. Young,et al. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer , 2015, Cell.
[20] D. Price,et al. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing. , 2015, Molecular cell.
[21] Fei Chen,et al. Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide , 2015, Genes & development.
[22] Yan Liu,et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. , 2014, Cancer cell.
[23] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[24] Bandana Sharma,et al. CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer , 2014, Cell.
[25] Sridhar Ramaswamy,et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.
[26] P. Kuzmič,et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance , 2013, Proceedings of the National Academy of Sciences.
[27] J. Lis,et al. Control of transcriptional elongation. , 2013, Annual review of genetics.
[28] Henning Hermjakob,et al. The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..
[29] Karl A. Merrick,et al. A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. , 2013, Molecular cell.
[30] David A. Orlando,et al. Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.
[31] Chao Zhang,et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II , 2012, Nature Structural &Molecular Biology.
[32] D. Ehmann,et al. Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor , 2012, Proceedings of the National Academy of Sciences.
[33] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[34] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[35] S. Edwards,et al. Mcl‐1; the molecular regulation of protein function , 2010, FEBS letters.
[36] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[37] Marco Foiani,et al. Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.
[38] Stéphane Larochelle,et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. , 2007, Molecular cell.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] R. Conaway,et al. Phosphorylation of C-terminal domain of RNA polymerase II is not required in basal transcription , 1993, Nature.
[41] Robert A. Copeland,et al. Evaluation of enzyme inhibitors in drug discovery , 2013 .
[42] E. Calura,et al. GRAPH Interaction from pathway Topological Environment , 2013 .